JP2022546806A5 - - Google Patents

Info

Publication number
JP2022546806A5
JP2022546806A5 JP2022513248A JP2022513248A JP2022546806A5 JP 2022546806 A5 JP2022546806 A5 JP 2022546806A5 JP 2022513248 A JP2022513248 A JP 2022513248A JP 2022513248 A JP2022513248 A JP 2022513248A JP 2022546806 A5 JP2022546806 A5 JP 2022546806A5
Authority
JP
Japan
Prior art keywords
aliphatic
group
tumor
independently
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513248A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546806A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2020/050932 external-priority patent/WO2021042171A1/en
Publication of JP2022546806A publication Critical patent/JP2022546806A/ja
Publication of JP2022546806A5 publication Critical patent/JP2022546806A5/ja
Priority to JP2025115718A priority Critical patent/JP2025148436A/ja
Pending legal-status Critical Current

Links

JP2022513248A 2019-09-04 2020-09-04 癌免疫療法 Pending JP2022546806A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025115718A JP2025148436A (ja) 2019-09-04 2025-07-09 癌免疫療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2019903262A AU2019903262A0 (en) 2019-09-04 Cancer immunotherapy
AU2019903262 2019-09-04
AU2019904864A AU2019904864A0 (en) 2019-12-20 Cancer immunotherapy (2)
AU2019904864 2019-12-20
PCT/AU2020/050932 WO2021042171A1 (en) 2019-09-04 2020-09-04 Cancer immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025115718A Division JP2025148436A (ja) 2019-09-04 2025-07-09 癌免疫療法

Publications (2)

Publication Number Publication Date
JP2022546806A JP2022546806A (ja) 2022-11-09
JP2022546806A5 true JP2022546806A5 (https=) 2023-09-12

Family

ID=74851930

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022513248A Pending JP2022546806A (ja) 2019-09-04 2020-09-04 癌免疫療法
JP2025115718A Pending JP2025148436A (ja) 2019-09-04 2025-07-09 癌免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025115718A Pending JP2025148436A (ja) 2019-09-04 2025-07-09 癌免疫療法

Country Status (6)

Country Link
US (1) US20230043518A1 (https=)
EP (1) EP4025204A4 (https=)
JP (2) JP2022546806A (https=)
CN (2) CN121371186A (https=)
AU (1) AU2020340468A1 (https=)
WO (1) WO2021042171A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2618842B1 (en) 2010-09-22 2019-04-24 Ena Therapeutics Pty Ltd Novel immunostimulatory method
AU2018391325B2 (en) 2017-12-21 2024-07-11 Axelia Oncology Pty Ltd Optimised compounds
MX2021015961A (es) 2019-06-26 2022-03-22 Ena Respiratory Pty Ltd Moleculas novedosas.
US20220347146A1 (en) * 2019-09-04 2022-11-03 Axelia Oncology Pty Ltd Cancer treatment
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100872472B1 (ko) * 2003-05-15 2008-12-05 도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬 면역자극제
GB0907989D0 (en) * 2009-05-08 2009-06-24 Hybrid Systems Ltd Multivalent adjuvant display
EP2618842B1 (en) * 2010-09-22 2019-04-24 Ena Therapeutics Pty Ltd Novel immunostimulatory method
CN113876945A (zh) * 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
EP3328418A1 (en) * 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
PL3429618T3 (pl) * 2016-03-16 2024-07-01 Amal Therapeutics Sa Kombinacja modulatora immunologicznego punktu kontrolnego i kompleks zawierający peptyd penetrujący komórkę, cargo i agonistę peptydu tlr do zastosowania w medycynie
CN110461351B (zh) * 2017-03-31 2024-03-26 艾娜呼吸私人有限公司 用tlr2激动剂治疗呼吸道感染
AU2018391325B2 (en) * 2017-12-21 2024-07-11 Axelia Oncology Pty Ltd Optimised compounds

Similar Documents

Publication Publication Date Title
JP2022546806A5 (https=)
JP2025060923A5 (https=)
US10722591B2 (en) Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof
JP2021521111A5 (https=)
JP2025160318A5 (https=)
JP2025160317A5 (https=)
JP2022542222A5 (https=)
JP2019043957A5 (https=)
CA3057715A1 (en) Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
JP2016505586A5 (https=)
JP2024542260A5 (https=)
JP2016510030A5 (https=)
JP2022546807A5 (https=)
JP2016521257A5 (https=)
RU2017145921A (ru) Пептидомиметические макроциклы
JP2013511540A5 (https=)
JP2013500304A5 (https=)
JP2016510030A (ja) 薬物組み合わせ
JP2020508985A5 (https=)
JP2022539091A5 (https=)
JP2022546806A (ja) 癌免疫療法
JP2021513990A5 (https=)
CN117551032A (zh) 包含喹啉衍生物的药物偶联物
WO2022177993A1 (en) Self-assembling nanoparticles based on amphiphilic peptides
BR112021001992A2 (pt) efeito adjuvante do agonista tlr1/2 diprovocim sinergiza com anticorpos inibidores de checkpoint para eliminar doença